Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis

References

• Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6(1):8. doi:10.1186/s40425-018-0316-z.
   PubMed Web of Science ®Google Scholar
• Marrone K, Ying W, Naidoo J. Immune-related adverse events from immune checkpoint inhibitors. Clin Pharmacol Ther. 2016;100(3):242–12. doi:10.1002/cpt.394.
   PubMed Web of Science ®Google Scholar
• Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13(8):473–486. doi:10.1038/nrclinonc.2016.58.
   PubMed Web of Science ®Google Scholar
• Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148. doi:10.1016/j.ejca.2015.11.016.
   PubMed Web of Science ®Google Scholar
• Nishijima TF, Shachar SS, Nyrop KA, Muss HB. Safety and tolerability of PD‐1/PD‐L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta‐analysis. Oncologist. 2017;22(4):470–479. doi:10.1634/theoncologist.2016-0419.
   PubMed Web of Science ®Google Scholar
• Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigentler TK, Grimm MO, Grünwald V, Leipe J, Reinmuth N, Tietze JK, et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA- 4): evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017;57:36–49. doi:10.1016/j.ctrv.2017.05.003.
   PubMed Web of Science ®Google Scholar
• Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi:10.1186/s12916-015-0455-8.
   PubMed Web of Science ®Google Scholar
• Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V, Kähler KC, Loquai C, Reinmuth N, Steins M, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7–18. doi:10.1016/j.ctrv.2016.02.003.
   PubMed Web of Science ®Google Scholar
• Zhang X, Ran YG, Wang KJ, Zhu YX, Li JH. Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. Drug Des Devel Ther. 2016;10:3153–3161. doi:10.2147/DDDT.S115493.
   PubMed Web of Science ®Google Scholar
• Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW, Liu N, Yan CX. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017;8:730. doi:10.3389/fphar.2017.00730.
   PubMed Web of Science ®Google Scholar
• Khunger M, Jain P, Rakshit S, Pasupuleti V, Hernandez AV, Stevenson J, Pennell NA, Velcheti V. Safety and efficacy of PD-1/PD-L1 inhibitors in treatment-naive and chemotherapy-refractory patients with non–small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer. 2018;19(3):e335–48. doi:10.1016/j.cllc.2018.01.002.
   PubMed Web of Science ®Google Scholar
• Pillai RN, Behera M, Owonikoko TK, Kamphorst AO, Pakkala S, Belani CP, Khuri FR, Ahmed R, Ramalingam SS. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature. Cancer. 2018;124(2):271–277. doi:10.1002/cncr.31043.
   PubMed Web of Science ®Google Scholar
• Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebbé C, Kirkwood JM, Schachter J, Daniels GA, et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol. 2017;35(34):3815–3822. doi:10.1200/JCO.2016.72.1167.
   PubMed Web of Science ®Google Scholar
• Wei W, Luo Z. Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: a meta-analysis of randomized clinical trials. Medicine (Baltimore). 2017;96(48):e8931. doi:10.1097/MD.0000000000008931.
   PubMed Web of Science ®Google Scholar
• Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, Motzer RJ, Wu S, Busam KJ, Wolchok JD, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12–25. doi:10.1016/j.ejca.2016.02.010.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. Immunotherapy. 2016;8(5):665–674. doi:10.2217/imt-2015-0020.
   PubMed Web of Science ®Google Scholar
• Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173–182. doi:10.1001/jamaoncol.2017.3064.
   PubMed Web of Science ®Google Scholar
• Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA, Velcheti V. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017;152(2):271–281. doi:10.1016/j.chest.2017.04.177.
   PubMed Web of Science ®Google Scholar
• Ciccarese C, Iacovelli R, Bria E, Modena A, Massari F, Brunelli M, Fantinel E, Bimbatti D, Zamboni GA, Artibani W, et al. The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD-1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. Immunotherapy. 2017;9(7):579–587. doi:10.2217/imt-2017-0018.
   PubMed Web of Science ®Google Scholar
• Hu YB, Zhang Q, Li HJ, Michot JM, Liu HB, Zhan P, Lv TF, Song Y. Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2017;6(Suppl 1):S8–20. doi:10.21037/tlcr.2017.12.10.
   PubMed Web of Science ®Google Scholar
• Abdallah K, Shulgin B, Peskov K, Kosinsky Y, Vergara-Silva A, Helmlinger G, Chu L, Masson E. Model-based meta-analysis of safety for immune checkpoint inhibitor combinations and monotherapy (ASCO abstract 89). J Clin Oncol. 2017;35(Suppl 7):89. doi:10.1200/JCO.2017.35.7_suppl.89.
   Web of Science ®Google Scholar
• Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L, Hamid O, Rutkowski P, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017;18(5):611–622. doi:10.1016/S1470-2045(17)30231-0.
   PubMed Web of Science ®Google Scholar
• Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35(1):40–47. doi:10.1200/JCO.2016.69.1584.
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–530. doi:10.1016/S1470-2045(15)70122-1.
   PubMed Web of Science ®Google Scholar
• Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res. 2013;19(14):3977–3986. doi:10.1158/1078-0432.CCR-12-3243.
   PubMed Web of Science ®Google Scholar
• Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377–2385. doi:10.1093/annonc/mdx286.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356. doi:10.1056/NEJMoa1709684.
   PubMed Web of Science ®Google Scholar
• Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, et al. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: a randomised clinical trial. Eur J Cancer. 2018;101:236–243. doi:10.1016/j.ejca.2018.06.034.
   PubMed Web of Science ®Google Scholar
• Créquit P, Chaimani A, Yavchitz A, Attiche N, Cadranel J, Trinquart L, Ravaud P. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis. BMC Med. 2017;15(1):193. doi:10.1186/s12916-017-0954-x.
   PubMed Web of Science ®Google Scholar
• Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–2471. doi:10.1016/S0140-6736(17)31827-5.
   PubMed Web of Science ®Google Scholar
• Owen DH, Wei L, Villalona-Calero MA, Bertino EM, He K, Shields PG, Carbone DP, Otterson GA. Impact of immune-related adverse events (irAE) on overall survival (OS) in patients treated with immunotherapy for non-small cell lung cancer (NSCLC). J Clin Oncol. 2017;35(15 suppl):9080. doi:10.1200/JCO.2017.35.15_suppl.9080.
   Web of Science ®Google Scholar
• Wu J, Hong D, Zhang X, Lu X, Miao J. PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. Sci Rep. 2017;7:44173. doi:10.1038/srep44173.
   PubMed Web of Science ®Google Scholar
• Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785–792. doi:10.1200/JCO.2015.66.1389.
   PubMed Web of Science ®Google Scholar
• Peng TR, Tsai F-P, Wu T-W. Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: a meta-analysis of randomized clinical trials. Int Immunopharmacol. 2017;49:85–94. doi:10.1016/j.intimp.2017.05.019.
   PubMed Web of Science ®Google Scholar
• Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Ueda H, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer. 2018;115:71–74. doi:10.1016/j.lungcan.2017.11.019.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. doi:10.1056/NEJMra1703481.
   PubMed Web of Science ®Google Scholar
• Palmieri DJ, Carlino MS. Immune checkpoint inhibitor toxicity. Curr Oncol Rep. 2018;20:72. doi:10.1007/s11912-018-0718-6.
   PubMed Web of Science ®Google Scholar
• Connolly C, Bambhania K, Naidoo J. Immune-related adverse events: a case-based approach. Front Oncol. 2019;9:530. doi:10.3389/fonc.2019.00530.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097.
   PubMed Web of Science ®Google Scholar
• TrialTrove: pharmaceutical clinical trials intelligence data. https://pharmaintelligence.informa.com/products-and-services/data-and-analysis/trialtrove [accessed 2018 Oct 10].
   Google Scholar
• Ahamadi M, Freshwater T, Prohn M, Li CH, de Alwis DP, de Greef R, Elassaiss‐Schaap J, Kondic A, Stone JA. Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharmacometrics Syst Pharmacol. 2017;6(1):49–57. doi:10.1002/psp4.12139.
   PubMedGoogle Scholar
• EMA557664, Assessment report for yervoy (ipilimumab) EMA/CHMP/557664/2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002213/WC500109302.pdf [accessed 2018 Sep 25].
   Google Scholar
• Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometrics Syst Pharmacol. 2017;6(1):58–66. doi:10.1002/psp4.12143.
   PubMedGoogle Scholar
• Baverel PG, Dubois VFS, Jin CY, Zheng Y, Song X, Jin X, Mukhopadhyay P, Gupta A, Dennis PA, Ben Y, et al. Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. Clin Pharmacol Ther. 2018;103(4):631–642. doi:10.1002/cpt.982.
   PubMed Web of Science ®Google Scholar
• BLA125514, Pharmacology review: keytruda (pembrolizumab), 2014. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125514Orig1s000PharmR.pdf [accessed 2018 Sep 25].
   Google Scholar
• BLA761034, Clinical pharmacology review: tecentriq (atezolizumab), 2016. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761034Orig1s000ClinPharmR.pdf [accessed 2018 Sep 25].
   Google Scholar
• BLA761049, Multidisciplinary review and evaluation: bavencio (avelumab), 2016. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761049Orig1s000MultidisciplineR.pdf [accessed 2018 Sep 25].
   Google Scholar
• BLA761069, Pharmacology review: imfinzi (durvalumab), 2017. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761069Orig1s000PharmR.pdf [accessed 2018 Sep 25].
   Google Scholar
• Stroh M, Winter H, Marchand M, Claret L, Eppler S, Ruppel J, Abidoye O, Teng SL, Lin WT, Dayog S, et al. Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma. Clin Pharmacol Ther. 2017;102(2):305–312. doi:10.1002/cpt.587.
   PubMed Web of Science ®Google Scholar
• Shah DK, Betts AM. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs. 2013;5(2):297–305. doi:10.4161/mabs.23684.
   PubMed Web of Science ®Google Scholar
• Kang D, Wang E, Wang D, Amantea M, Hsyu P. Population pharmacokinetics (PK) of tremelimumab in patients (pts) with melanoma. J Clin Oncol. 2009;27:3048.
   Web of Science ®Google Scholar
• Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846–856. doi:10.1158/2326-6066.CIR-14-0040.
   PubMed Web of Science ®Google Scholar
• Sheng J, Srivastava S, Sanghavi K, Lu Z, Schmidt BJ, Bello A, Gupta M. Clinical pharmacology considerations for the development of immune checkpoint inhibitors. J Clin Pharmacol. 2017;57(Suppl 10):S26–42. doi:10.1002/jcph.990.
   PubMed Web of Science ®Google Scholar
• Tremelimumab. Drugs R D. 2010;10(2):123–132. doi:10.2165/11584530-000000000-00000.
   PubMedGoogle Scholar
• Hamza TH, van Houwelingen HC, Stijnen T. The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol. 2008;61(1):41–51. doi:10.1016/j.jclinepi.2007.03.016.
   PubMed Web of Science ®Google Scholar
• Stijnen T, Hamza TH, Özdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med. 2010;29(29):3046–3067. doi:10.1002/sim.4040.
   PubMed Web of Science ®Google Scholar
• Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3). doi:10.18637/jss.v036.i03.
   PubMed Web of Science ®Google Scholar
• Boixader LV, Curtis KK, Wahl J, Kenny N, Moss KR. Changes in numbers of randomized (RCT) versus non-randomized (NRCT) clinical trials from 2004–2016: evidence of shifting cancer drug development pathway. J Clin Oncol. 2017;35(15 suppl):2543. doi:10.1200/JCO.2017.35.15_suppl.2543.
   Web of Science ®Google Scholar
• Grossman Z, Paul WE. Dynamic tuning of lymphocytes: physiological basis, mechanisms, and function. Annu Rev Immunol. 2015;33:677–713. doi:10.1146/annurev-immunol-032712-100027.
   PubMed Web of Science ®Google Scholar
• Hogquist KA, Jameson SC. The self-obsession of T cells: how TCR signaling thresholds affect fate ‘decisions’ and effector function. Nat Immunol. 2014;15(9):815–823. doi:10.1038/ni.2938.
   PubMed Web of Science ®Google Scholar
• Sinclair NR, Anderson CC. Co-stimulation and co-inhibition: equal partners in regulation. Scand J Immunol. 1996;43(6):597–603. doi:10.1046/j.1365-3083.1996.d01-267.x.
   PubMed Web of Science ®Google Scholar
• Bakacs T, Moss RW, Kleef R, Szasz MA, Anderson CC. Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancer. Scand J Immunol. 2019;90(6):e12821. doi:10.1111/sji.12821.
   PubMed Web of Science ®Google Scholar
• Renner A, Burotto M, Rojas C. Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancer. immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy? J Glob Oncol. 2019;5:1–5. doi:10.1200/JGO.19.00142.
   PubMed Web of Science ®Google Scholar
• Chatterjee MS, Elassaiss-Schaap J, Lindauer A, Turner DC, Sostelly A, Freshwater T, Mayawala K, Ahamadi M, Stone JA, de Greef R, et al. Population pharmacokinetic/pharmacodynamic modeling of tumor size dynamics in pembrolizumab-treated advanced melanoma. CPT Pharmacometrics Syst Pharmacol. 2017;6(1):29–39. doi:10.1002/psp4.12140.
   PubMedGoogle Scholar
• Agrawal S, Feng Y, Roy A, Kollia G, Lestini B. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer. 2016;4:72. doi:10.1186/s40425-016-0177-2.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie Jr T, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–164. doi:10.1016/S1470-2045(09)70334-1.
   PubMed Web of Science ®Google Scholar
• Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):501–508. doi:10.1016/S1470-2045(12)70006-2.
   PubMed Web of Science ®Google Scholar
• Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009;27(7):1075–1081. doi:10.1200/JCO.2008.19.2435.
   PubMed Web of Science ®Google Scholar
• Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S, Gnjatic S, Berman D. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother. 2012;35(1):89–97. doi:10.1097/CJI.0b013e31823aa41c.
   PubMed Web of Science ®Google Scholar
• Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med. 2008;1(6):22. doi:10.1186/1479-5876-6-22.
   Web of Science ®Google Scholar
• Wei SC, Anang NAS, Sharma R, Andrews MC, Reuben A, Levine JH, Cogdill AP, Mancuso JJ, Wargo JA, Pe’er D, et al. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc Natl Acad Sci U S A. 2019;116(45):22699–22709. doi:10.1073/pnas.1821218116.
   PubMed Web of Science ®Google Scholar
• Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, Fong L. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med. 2014;6(238):238ra70. doi:10.1126/scitranslmed.3008211.
   PubMed Web of Science ®Google Scholar
• Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, Mok S, Huang RR, Cochran AJ, Comin-Anduix B, et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 2014;20(9):2424–2432. doi:10.1158/1078-0432.CCR-13-2648.
   PubMed Web of Science ®Google Scholar
• Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph-Pietras D, Welters MJ, van der Burg S, Kapiteijn E, Michielin O,et al. Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med. 2014;6(254):254ra128. doi:10.1126/scitranslmed.3008918
   PubMed Web of Science ®Google Scholar
• Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A. 2016;113(42):11919–11924. doi:10.1073/pnas.1611421113.
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–1086. doi:10.1158/2159-8290.CD-18-0367.
   PubMed Web of Science ®Google Scholar
• Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. Cancer Cell. 2019;35(2):238–255.e6. doi:10.1016/j.ccell.2019.01.003.
   PubMed Web of Science ®Google Scholar
• Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, Gherardini PF, Prestwood TR, Chabon J, Bendall SC, et al. Systemic immunity is required for effective cancer immunotherapy. Cell. 2017;168(3):487–502.e15. doi:10.1016/j.cell.2016.12.022.
   PubMed Web of Science ®Google Scholar
• Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, McNamara KL, Granja JM, Sarin KY, Brown RA, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019;25(8):1251–1259. doi:10.1038/s41591-019-0522-3.
   PubMed Web of Science ®Google Scholar
• Ellestad KK, Anderson CC. Two strikes and you’re out? The pathogenic interplay of coinhibitor deficiency and lymphopenia-induced proliferation. J Immun. 2017;198:2534–2541. doi:10.4049/jimmunol.1601884.
   PubMed Web of Science ®Google Scholar
• Ellestad KK, Lin J, Boon L, Anderson CC. PD-1 controls tonic signaling and lymphopenia-induced proliferation of T lymphocytes. Front Immunol. 2017;8:1289. doi:10.3389/fimmu.2017.01289.
   PubMed Web of Science ®Google Scholar
• Ellestad KK, Thangavelu G, Haile Y, Lin J, Boon L, Anderson CC. Prior to peripheral tolerance, newly generated CD4 T cells maintain dangerous autoimmune potential: fas- and perforin-independent autoimmunity controlled by programmed death-1. Front Immunol. 2018;9:12. doi:10.3389/fimmu.2018.00012.
   PubMed Web of Science ®Google Scholar
• Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, Hughes TA, Carter CR. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res. 2016;18(1):10. doi:10.1186/s13058-015-0669-x.
   PubMed Web of Science ®Google Scholar
• Carlino MS, Sandhu S. Safety and efficacy implications of discontinuing combination ipilimumab and nivolumab in advanced melanoma. J Clin Oncol. 2017;35(34):3792–3793. doi:10.1200/JCO.2017.75.2055.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–499. doi:10.1038/nri3862.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–1508. doi:10.1016/S1470-2045(16)30498-3.
   PubMed Web of Science ®Google Scholar
• Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, et al. Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non–small-cell lung cancer. J Clin Oncol. 2017;35:3449–3457. doi:10.1200/JCO.2016.71.7629.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez‑Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. doi:10.1056/NEJMoa1801005.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Chen C, Zhang X, Fu S, Xue C, Ma Y, Fang W, Yang Y, Hou X, Huang Y, et al. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis. J Immun Cancer. 2018;6(1):155. doi:10.1186/s40425-018-0477-9.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690–714. doi:10.1016/j.ccell.2015.10.012.
   PubMed Web of Science ®Google Scholar
• Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018;363:k4226. doi:10.1136/bmj.k4226.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Aguilera JV, Chintakuntlawar A, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008–1019. doi:10.1001/jamaoncol.2019.0393.
   PubMed Web of Science ®Google Scholar
• El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. 2017;119:1–12. doi:10.1016/j.critrevonc.2017.09.002.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020–2031. doi:10.1056/NEJMoa1910231.
   PubMed Web of Science ®Google Scholar
• Yoo SH, Keam B, Kim M, Kim SH, Kim YJ, Kim TM, Kim DW, Lee JS, Heo DS. Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. ESMO Open. 2018 Jul 25;3(5):e000332. doi:10.1136/esmoopen-2018-000332.
   PubMed Web of Science ®Google Scholar
• Schwarze JK, Vandersleyen V, Awada G, Jansen Y, Seremet T, Neyns B. A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM). JCO. 2019;37(15_suppl):9585. doi:10.1200/JCO.2019.37.15_suppl.9585.
   Web of Science ®Google Scholar
• Sen S, Hess KR, Hong DS, Naing A, Huang L, Meric-Bernstam F, Subbiah V. Impact of immune checkpoint inhibitor dose on toxicity, response rate, and survival: a pooled analysis of dose escalation phase 1 trials. JCO. 2018;36(15_suppl):3077. doi:10.1200/JCO.2018.36.15_suppl.3077.
   PubMed Web of Science ®Google Scholar